How to access Mekinist from Bahrain — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Bahraini patient diagnosed with BRAF V600 mutant advanced melanoma — or another approved BRAF-mutant indication — may receive a prescription for Mekinist (trametinib) from their treating medical oncologist, typically in combination with Tafinlar (dabrafenib). Mekinist is FDA-approved in the United States. In the Kingdom of Bahrain, Mekinist may not always be locally registered or routinely stocked, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Mekinist is an oral selective MEK1/MEK2 kinase inhibitor. It is used in combination with dabrafenib (Tafinlar) in BRAF V600 mutant cancers, improving both efficacy and tolerability versus BRAF-inhibitor monotherapy. The manufacturer is Novartis. Dosing is typically 2 mg orally once daily, taken on an empty stomach. Monitoring includes cardiac function (LVEF), ocular events (retinopathy, retinal vein occlusion), interstitial lung disease, skin rash, and hypertension. Your oncologist will confirm BRAF status and combination planning.
Is Mekinist legally importable into Bahrain?
Yes — through the Bahrain National Health Regulatory Authority (NHRA) named-patient import framework, administered via the administering hospital's importing pharmacy and the NHRA Pharmaceutical Product Regulation department.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are typically filed by the tertiary centre's importing pharmacy on the physician's behalf.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Mekinist in combination with Tafinlar is clinical, based on BRAF status and disease burden. Your oncologist documents the rationale.
- Administering facility identification. A Bahraini tertiary oncology centre with an importing pharmacy files on behalf of the physician.
- NHRA named-patient application. Your physician or the hospital's importing pharmacy files an application with NHRA including clinical rationale, combination regimen, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Mekinist tablets require controlled storage; shipments travel with temperature logging and tamper-evident packaging end to end.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming BRAF status, tumour type, combination regimen, prior therapies, and Mekinist as the indicated treatment
- Verification of their Bahrain medical licence (NHRA)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference preferred)
- The planned treatment cadence (continuous daily therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit bundling the templates NHRA reviewers expect to see for oncology oral therapies under named-patient import.
Costs and timing
Mekinist's US cash-pay reference price for a 30-day supply sits in an indicative 2026 range of roughly USD 13,000–15,000. The combination partner (Tafinlar) is costed separately. Logistics, NHRA documentation handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete NHRA application is submitted. Subsequent re-supply cycles are generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Mekinist specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for NHRA review, covering the full combination regimen.
- Logistics. Temperature-controlled shipment and chain-of-custody coordination.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Bahrain? Yes, when executed through the NHRA named-patient framework with appropriate documentation. See our trust and compliance page.
Can Mekinist and Tafinlar be coordinated together? Yes — the combination is standard of care; we coordinate both components under a single case.
What about cardiac and ocular monitoring? MEK inhibitors require periodic LVEF and ophthalmology review. Your oncologist will arrange this. We coordinate supply, not clinical surveillance.
Will private insurance cover this? Cash-pay is the default. Some Bahraini private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Mekinist coordination in Bahrain.
Add me to the Mekinist waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.